On Friday, Men’s Wearhouse Inc (NYSE:MW)’s shares inclined 0.50% to $64.41.
The Men’s Wearhouse (MW) declared it has signed a 10-year agreement with Macy’s, Inc. to operate men’s tuxedo rental shops inside 300 Macy’s stores. No other terms were revealed.
The new Macy’s Tuxedo Shop is predictable to be located in or near the Men’s Department and will have dedicated space staffed by our formalwear professionals. The Men’s Wearhouse will start operating 17 pilot tuxedo shops in fall 2015, then start the rollout of the remaining shops with the expectation that 300 shops will be open by fall 2016. Macy’s and Men’s Wearhouse will also collaborate to develop a digital tuxedo rental shop on macys.com.
The Men’s Wearhouse, Inc. operates as a specialty apparel retailer in the United States, Puerto Rico, and Canada. The company operates in two segments, Retail and Corporate Apparel. The Retail segment offers suits, suit separates, sport coats, slacks, formalwear, business casual, sportswear, outerwear, dress shirts, dress pants, overcoats, ties, shoes, and accessories for men in classic, modern, and slim fits in various sizes; and a selection of tuxedo rental products. It also offers ladies’ career apparel, sportswear, shoes, and accessories; children’s apparel; alteration services; and retail dry cleaning, laundry, and heir looming services.
Learning Tree International, Inc. (NASDAQ:LTRE)’s shares dropped -5.92% to $1.59.
Learning Tree International, Inc. (LTRE) has declared the introduction of their new Activity-Based Intelligence training curriculum and certifications. Activity-Based Intelligence (ABI) is an intelligence-oriented data analysis approach that harnesses new technologies and processes for efficient, real-time diverse data analysis.
Learning Tree International, Inc., together with its auxiliaries, develops, markets, and delivers a library of instructor-led classroom courses for professional development needs of information technology (IT) professionals and managers worldwide. It offers education and training courses across a range of technical and administration disciplines, such as operating systems, databases, computer networks, computer and network security, Web development, programming languages, software engineering, open source applications, project administration, business skills, leadership, and professional development.
At the end of Friday’s trade, Anthem Inc (NYSE:ANTM)‘s shares dipped -0.11% to $165.06.
Anthem Inc (ANTM) has placed a takeover bid for Cigna Corp. (CI). There have actually been 2 takeover bids in the last 10 days, the last one priced at $175 per share. The companies have been in talk aboution about the possibility of a takeover for a few months, but Cigna has thus far denied Anthem’s offers.
Cigna’s stocks surged to a 52-week high of $164 on heels of the news coming about, before decreasing to $153.43 to close out the day, a figure that is still a double digit enhance for the session. Anthem’s stock price saw an enhance of $3.75 or 2.33% to $164.46 as of the same time.
The health-insurance industry is in the midst of a major consolidation trend, and the news of Anthem’s bids comes at a time when the industry faces pressures to cut costs and explore all opportunities stemming from the Affordable Care Act. Because of the Act though, U.S. health insurers have been trading at all time highs due to the influx of new business. It also brought new fees that have affected providers’ profit margins.
Anthem, Inc., through its auxiliaries, operates as a health benefits company in the United States. It operates through three segments: Commercial and Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small employer, individual, Medicaid, and senior markets. Its managed care plans comprise preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products.
Heron Therapeutics Inc (NASDAQ:HRTX), ended its Friday’s trading session with 0.62% gain, and closed at $32.45.
Heron Therapeutics, Inc. (HRTX) declared recently that it has initiated a Phase 2 clinical trial of HTX-011, the Company’s lead product candidate for the prevention of post-operative pain, following clearance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for HTX-011. HTX-011, which utilizes Heron’s proprietary Biochronomer® drug delivery technology, is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam.
The placebo-controlled, dose-finding, Phase 2 clinical trial in about 60 patients undergoing bunionectomy will evaluate the efficacy and safety of HTX-011, containing 200 mg or 400 mg of bupivacaine combined with meloxicam, contrast to placebo. In a formerly accomplished, placebo-controlled, Phase 1 clinical trial of HTX-011 in healthy volunteers, the desired pharmacokinetic profile for both bupivacaine and meloxicam was achieved, with therapeutically relevant drug levels of bupivacaine sustained for 2-3 days. Heron anticipates reporting top-line results from this Phase 2 clinical trial in the second half of 2015.
Heron Therapeutics, Inc. is a biotechnology company. The Company is using its proprietary technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action of known active ingredients. Heron’s product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
